126 related articles for article (PubMed ID: 31611061)
21. [Pseudomonas aeruginosa infections].
Tanaka E
Naika; 1972; 29(2):286-90. PubMed ID: 4622605
[No Abstract] [Full Text] [Related]
22. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa.
Pilmis B; Petitjean G; Lesprit P; Lafaurie M; El Helali N; Le Monnier A;
Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1457-1461. PubMed ID: 31073653
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
[TBL] [Abstract][Full Text] [Related]
24. First report of a Pseudomonas aeruginosa clinical isolate co-harbouring KPC-2 and IMP-18 carbapenemases.
Martínez T; Vázquez GJ; Aquino EE; Ramírez-Ronda R; Robledo IE
Int J Antimicrob Agents; 2012 Jun; 39(6):542-3. PubMed ID: 22521765
[No Abstract] [Full Text] [Related]
25. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical.
Sorlí L; Luque S; Li J; Campillo N; Danés M; Montero M; Segura C; Grau S; Horcajada JP
J Infect; 2019 Sep; 79(3):253-261. PubMed ID: 31265867
[TBL] [Abstract][Full Text] [Related]
26. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
[TBL] [Abstract][Full Text] [Related]
27. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis.
Takata T; Aizawa K; Shimizu A; Sakakibara S; Watabe H; Totsuka K
J Infect Chemother; 2004 Apr; 10(2):76-85. PubMed ID: 15160299
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
29. Multicenter study of the sensitivity of Pseudomonas aeruginosa to antimicrobial agents.
Wiedemann B; Machka K; Malottke R
Eur J Clin Microbiol; 1985 Apr; 4(2):229-30. PubMed ID: 3924613
[No Abstract] [Full Text] [Related]
30. Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.
Lin YW; Zhou QT; Han ML; Onufrak NJ; Chen K; Wang J; Forrest A; Chan HK; Li J
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263069
[TBL] [Abstract][Full Text] [Related]
31. [Drug resistance of imipenem-resistant Pseudomonas aeruginosa of lower respiratory tract in pulmonary heart disease of coal worker's pneumoconiosis].
Yu J; Sun YX; Zhang CH
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Apr; 26(4):236-7. PubMed ID: 18724901
[No Abstract] [Full Text] [Related]
32. [Antibiotic therapy of Pseudomonas aeruginosa infections: possibilities and limitations].
Voiculescu M; Golăescu M; Giuglea M; Mătuşa R; Alexandru S
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1978; 30(2):157-64. PubMed ID: 26955
[No Abstract] [Full Text] [Related]
33. [Sensitivity in vitro to antibiotics and chemotherapeutic agents in various hospital strains of Pseudomonas aeruginosa].
Bertaggia A; De Negri M
Boll Ist Sieroter Milan; 1974; 50(1):45-53. PubMed ID: 4204863
[No Abstract] [Full Text] [Related]
34. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam.
Bhagunde P; Zhang Z; Racine F; Carr D; Wu J; Young K; Rizk ML
Int J Infect Dis; 2019 Dec; 89():55-61. PubMed ID: 31479762
[TBL] [Abstract][Full Text] [Related]
35. [Trend of therapy in Pseudomonas aeruginosa infections].
Jannuzzi C; Tassara A
G Mal Infett Parassit; 1971 Nov; 23(11):1051-4. PubMed ID: 5004852
[No Abstract] [Full Text] [Related]
36. [Role of antibiotics in infections due to Pseudomonas aeruginosa].
Výmola F; Jedlicková Z
Cesk Epidemiol Mikrobiol Imunol; 1972 Jul; 21(4):176-81. PubMed ID: 4262242
[No Abstract] [Full Text] [Related]
37. A report of Pseudomonas aeruginosa antibiotic resistance from a multicenter study in Iran.
Boroumand MA; Esfahanifard P; Saadat S; Sheihkvatan M; Hekmatyazdi S; Saremi M; Nazemi L
Indian J Med Microbiol; 2007 Oct; 25(4):435-6. PubMed ID: 18087112
[No Abstract] [Full Text] [Related]
38. Pseudomonas aeruginosa bacteraemia in burns patients: Risk factors and outcomes.
Mahar P; Padiglione AA; Cleland H; Paul E; Hinrichs M; Wasiak J
Burns; 2010 Dec; 36(8):1228-33. PubMed ID: 20965109
[TBL] [Abstract][Full Text] [Related]
39. Pseudomonas endocarditis in the Detroit Medical Center. 1969-1972.
Reyes MP; Palutke WA; Wylin RF
Medicine (Baltimore); 1973 May; 52(3):173-94. PubMed ID: 20407410
[No Abstract] [Full Text] [Related]
40. Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.
Kristoffersson AN; David-Pierson P; Parrott NJ; Kuhlmann O; Lave T; Friberg LE; Nielsen EI
Pharm Res; 2016 May; 33(5):1115-25. PubMed ID: 26786016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
